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ofOBJECTIVES This study sought to develop a clinical model that identiﬁes patients with and without high-risk coronary
artery disease (CAD).
BACKGROUND Although current clinical models help to estimate a patient’s pre-test probability of obstructive CAD,
they do not accurately identify those patients with and without high-risk coronary anatomy.
METHODS Retrospective analysis of a prospectively collected multinational coronary computed tomographic angiog-
raphy (CTA) cohort was conducted. High-risk anatomy was deﬁned as left main diameter stenosis$50%, 3-vessel disease
with diameter stenosis $70%, or 2-vessel disease involving the proximal left anterior descending artery. Using a cohort
of 27,125, patients with a history of CAD, cardiac transplantation, and congenital heart disease were excluded. The model
was derived from 24,251 consecutive patients in the derivation cohort and an additional 7,333 nonoverlapping patients in
the validation cohort.
RESULTS The risk score consisted of 9 variables: age, sex, diabetes, hypertension, current smoking, hyperlipidemia,
family history of CAD, history of peripheral vascular disease, and chest pain symptoms. Patients were divided into 3 risk
categories: low (#7 points), intermediate (8 to 17 points) and high ($18 points). The model was statistically robust with
area under the curve of 0.76 (95% conﬁdence interval [CI]: 0.75 to 0.78) in the derivation cohort and 0.71 (95% CI: 0.69
to 0.74) in the validation cohort. Patients who scored #7 points had a low negative likelihood ratio (<0.1), whereas
patients who scored $18 points had a high speciﬁcity of 99.3% and a positive likelihood ratio (8.48). In the validation
group, the prevalence of high-risk CAD was 1% in patients with #7 points and 16.7% in those with $18 points.
CONCLUSIONS We propose a scoring system, based on clinical variables, that can be used to identify patients at high
and low pre-test probability of having high-risk CAD. Identiﬁcation of these populations may detect those who may
beneﬁt from a trial of medical therapy and those who may beneﬁt most from an invasive strategy. (J Am Coll Cardiol Img
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CAD = coronary artery disease
CTA = computed tomographic
angiography
HRA = high-risk anatomy
ICA = invasive coronary
angiography
ROC = receiver operating
characteristic
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428T he diagnosis and subsequent strati-ﬁcation of patients with suspectedcoronary artery disease (CAD) are
important to management. Traditionally, pa-
tients with CAD are categorized according to
the presence and absence of high-risk coro-
nary anatomy because those patients with
high-risk CAD often derive the greatest mor-
tality beneﬁt with revascularization (1–3).
Conversely, a trial of optimal medical ther-apy may be appropriate for those patients with non–
high-risk CAD (4).SEE PAGE 435The current standard for the anatomic diagnosis
of CAD is invasive coronary angiography (ICA);
however, ICA is expensive and has associated proce-
dural hazards (5). Therefore, it would be desirable to
identify patients at greatest probability of high-risk
CAD who require further investigations and those
patients with low probability of high-risk CAD in
whom a trial of optimal medical therapy may be
appropriate. Current clinical models estimate a pa-
tient’s pre-test probability for obstructive CAD, but
they do not accurately predict the presence or
absence of high-risk CAD (left main coronary artery
diameter stenosis $50%, 3-vessel disease [diameter
stenosis $70%] or 2-vessel disease involving the
proximal left anterior descending artery). Previous
models have deﬁned signiﬁcant CAD as $1 vessel with
a $50% or $75% lesion (6–8). To our knowledge, no
studies have examined models to ascertain likelihood
of ‘high-risk coronary anatomy’. This is most relevant
given recent evidence that optimal medical therapy is
a reasonable treatment option in patients with CAD.
Using a large, prospective international registry of
patients referred to coronary computed tomographic
angiography (CTA) for suspected CAD, this studyy, Weill Cornell Medical College and the New York Presbyterian
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METHODS
PATIENTS AND EXCLUSION CRITERIA. Patients
referred to coronary CTA for suspected CAD were
included in the study. Patients with documented CAD
or a history of myocardial infarction, coronary
revascularization, cardiac transplantation, and con-
genital heart disease were excluded from analysis.
Between 2005 and 2009, 27,125 consecutive adult
patients $18 years old who were undergoing $64-
detector row coronary CTA were prospectively
enrolled into the CONFIRM (Coronary CT Angiog-
raphy Evaluation for Clinical Outcomes: An Interna-
tional Multicenter) registry and were used for the
derivation cohort (9). Using the same inclusion and
exclusion criteria, an additional nonoverlapping
cohort (comprising the CONFIRM validation cohort
and the University of Ottawa Heart Institute Cardiac
CT Registry) of 7,333 patients was used as a validation
cohort.
Each center obtained approval from the Institu-
tional Review Board, and all patients provided
informed consent for study participation.
CLINICAL DEFINITIONS. At the time of coronary
CTA, medical history and available laboratory results
were recorded for all patients (6,10). A detailed
description of the methods has been previously
published (9). Symptoms were analyzed according to
the criteria for angina pectoris, in which patients with
typical angina exhibited all 3 characteristics (chest
pain, onset with exertion, improvement with rest)
and atypical angina with any 1 or 2 characteristics (6).
Hypertension was deﬁned as a known history of
systolic blood pressure >140 mm Hg or treatment
with antihypertensive medications. Diabetes mellitus
was deﬁned as a previous diagnosis of diabetes or useHospital, New York, New York; ****Department of
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429of oral hypoglycemic drugs or insulin. Dyslipidemia
was deﬁned as a known history of dyslipidemia or
treatment with lipid-lowering agents. Family history
of premature CAD was deﬁned as a ﬁrst-degree rela-
tive with myocardial infarction (<55 years for men,
<65 years for women). The CONFIRM registry used
standardized deﬁnitions of cardiovascular risk factors
for data collection to minimize differences among
centers (9,10). Sites with at least 80% overlap with
predeﬁned data dictionary were enrolled into the
CONFIRM registry, and they had uniform collection of
major categories of patient information including
demographics and cardiovascular risk factors (9).
To compare our model with existing models, the
pre-test probability of obstructive CAD ($50% diam-
eter stenosis) was calculated for each patient ac-
cording to age, sex, and type of chest pain by using
the updated Diamond-Forrester model (11).
CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY.
Coronary CTA image acquisition and interpretation,
as previously described, were performed according
to clinical routine at each participating center using
single- or dual-source 64-slice CT scanners (9).
Coronary artery diameter stenosis was graded using
a 4-point score (normal or mild, <50%; moderate,
50% to 69%; or severe, $70%) (12). Patients were
further categorized according to the presence and
absence of high-risk CAD, deﬁned as left main cor-
onary artery stenosis ($50%), 3-vessel disease
($70%), or 2-vessel disease ($70%) involving the
proximal left anterior descending artery (13,14).
Previous study has shown that coronary CTA is a
highly speciﬁc and sensitive method for detecting
high-risk anatomy compared with ICA (sensitivity,
100%; speciﬁcity, 95%) (15).
STATISTICAL ANALYSIS. Statistical analysis was
performed using SAS 9.2 software (version 9.2, SAS
Institute Inc., Cary, North Carolina). Statistical sig-
niﬁcance was deﬁned as p < 0.05. Continuous vari-
ables were presented as means and standard
deviations, and categorical variables were presented
as frequencies with percentages. To compare pa-
tients’ characteristics, Student t test was used for
continuous variables and chi-square test was used for
categorical variables.
All clinical variables potentially associated with
high-risk coronary anatomy were evaluated. Medica-
tions and diagnostic tests were excluded to obtain a
model based entirely on clinical history. Variables for
which more than 10% of data was missing were not
included in the analysis (cerebrovascular disease).
Using these criteria, the variables of age, sex, symp-
toms, diabetes, current smoking, family history ofcardiovascular disease, hypertension, body mass in-
dex, hyperlipidemia and history of peripheral vas-
cular disease were identiﬁed for univariable analysis.
Variables statistically signiﬁcant in the univariable
analysis (deﬁned as p < 0.1 to include more variables)
were included in a multivariable logistic regression
model. Interaction between sex and other variables in
the multivariable model was examined to explore for
differences between male and female patients. From
this model, a scoring system was developed by
assigning points for each variable using the method
demonstrated by the Framingham Risk Score (16). The
classiﬁcation performance of this score was evaluated
using sensitivity, speciﬁcity, positive or negative
predictive values, and likelihood ratios with 95%
conﬁdence interval (CI) by applying this score in the
derivation cohort. The receiver operating character-
istic (ROC) curves for the score were generated. The
area under the ROC curve with 95% CI was calculated
to evaluate the discrimination ability of the score
over the updated Diamond-Forrester model in pre-
dicting high-risk CAD by using method proposed by
DeLong et al. (17). To assess the applicability of the
score to a population with a higher clinical risk, the
model was also applied to a subgroup of symptomatic
patients (with either chest pain or dyspnea) in the
derivation cohort. The calibration of the score was
assessed using the Hosmer-Lemeshow statistic,
where p < 0.05 indicates an inadequate ﬁt. The pre-
diction accuracy and classiﬁcation performance of the
score were also validated using an external validation
cohort.
RESULTS
A total of 35,711 consecutive patients (derivation
cohort, 27,125 patients; and validation cohort, 8,586
patients) from 12 sites in 6 countries across North
America, Europe, and Asia were screened. Excluding
patients with a history of coronary revascularization,
cardiac transplantation, myocardial infarction, or
congenital heart disease (n ¼ 2,874), the derivation
cohort comprised 24,251 patients, with 3.6% (877)
patients with high-risk CAD. Of these, 14,142 patients
were symptomatic with either chest pain or shortness
of breath. Results of the derivation cohort were vali-
dated in an external validation set consisting of 7,333
patients, after excluding 1,253 patients for missing
data (Table 1); 4.8% (n ¼ 349) of patients in the vali-
dation cohort had high-risk CAD.
DERIVATION COHORT. Using univariable analysis,
age, sex, hyperlipidemia, hypertension, diabetes,
current smoking, family history, history of peripheral
vascular disease and chest pain symptoms were
TABLE 2 Multivariab
B
Age 0.0
Male 1.0
Diabetes 0.5
Hyperlipidemia 0.2
Hypertension 0.1
Current smoking 0.5
Symptoms 0.2
Family history 0.6
PVD 0.6
CI ¼ conﬁdence interval; o
TABLE 3 Scoring Method*
Points
Age, yrs
<30 -1
30–39 0
40–49 2
50–59 4
60–69 6
70–79 8
$80 10
Male 3
Symptoms
Asymptomatic 0
Nonanginal/atypical chest pain 1
Typical angina 2
Family history of CAD 2
History of PVD 2
Diabetes 2
Current smoking 2
Hyperlipidemia 1
Hypertension 1
*Clinical probability: low risk, #7 points; intermediate risk, 8–17 points; high
risk, $18 points.
Abbreviations as in Table 1.
TABLE 1 Clinical Characteristics of Derivation and Validation Cohorts
Derivation Cohort Validation Cohort
High-Risk CAD
(N ¼ 877)
Non–High-Risk CAD
(N ¼ 23,374)
High-Risk CAD
(N ¼ 349)
Non–High-Risk CAD
(N ¼ 6,984)
Mean age, yrs 66.0  10.5 57.2  12.6 63.8  10.3 57.3  11.7
Mean BMI, kg/m2 27.6  5.0 27.5  5.3 27.6  4.9 28.8  7.0
Male 616 (70.2) 12,537 (53.6) 242 (69.3) 3,671 (52.6)
Hypertension 546 (62.3) 11,563 (49.5) 241 (69.1) 3,799 (54.4)
Diabetes 227 (25.9) 3,340 (14.3) 136 (39.0) 1,393 (20.0)
Hyperlipidemia 578 (65.9) 12,753 (54.6) 199 (57.0) 3,591 (51.4)
Current smoking 201 (22.9) 4,101 (17.6) 86 (24.6) 1,313 (18.8)
PVD history 37 (4.2) 373 (1.6) 14 (4.0) 217 (3.1)
Symptoms
Asymptomatic 217 (24.7) 7,536 (32.2) 103 (29.5) 2,316 (33.2)
Atypical 447 (50.4) 12,423 (53.1) 155 (44.4) 3,509 (50.2)
Typical 213 (24.3) 3,415 (14.6) 91 (26.1) 1,159 (16.6)
Family history of CAD 420 (47.9) 8,448 (36.1) 98 (28.1) 2,752 (39.4)
Ethnicity
Caucasian 315 (35.9) 7,154 (30.6) N/A N/A
African 19 (2.17) 885 (3.79)
Latin America 39 (4.4) 317 (1.62)
East Asian 62 (7.07) 4,244 (18.2)
South Asian 2 (0.23) 62 (0.27)
Middle Eastern 12 (1.37) 148 (0.63)
Other/mixed 0 92 (0.39)
Unknown 428 (48.8) 10,472 (44.8)
Values are mean  SD or n (%).
BMI ¼ body mass index; CAD ¼ coronary artery disease; N/A ¼ not available; PVD ¼ peripheral vascular
disease.
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430associated with high-risk CAD and used in a multi-
variable logistic analysis to generate the ﬁnal model
(Table 2). Interaction between sex and other variables
was examined and was found to be insigniﬁcant.
Points for each variable were assigned based on its
regression coefﬁcient to generate a scoring system
(Table 3). Using the score from 1 to 25, the predictive
probability of high-risk CAD ranged from 0.1% (95%
CI: 0.1 to 0.1) to 51.1% (95% CI: 45.6 to 56.6). The
diagnostic value for each threshold of high-risk CAD
score was calculated (Table 4). Based on positive andle Model for High-Risk CAD
eta Standard Error Odds Ratio Lower CI Upper CI p Value
67 0.003 1.069 1.063 1.076 <0.001
08 0.078 2.739 2.350 3.192 <0.001
28 0.083 1.695 1.440 1.995 <0.001
21 0.076 1.248 1.076 1.447 0.003
33 0.076 1.143 0.985 1.325 0.077
16 0.087 1.675 1.414 1.985 <0.001
11 0.033 1.235 1.158 1.317 <0.001
00 0.072 1.822 1.584 2.096 <0.001
33 0.185 1.883 1.310 2.708 <0.001
ther abbreviations as in Table 1.negative likelihood ratios, 3 categories were derived:
low (#7 points), intermediate (8 to 17 points), and
high ($18 points), and the prevalence of CAD was
calculated for each probability group (Table 5). Pa-
tients who scored #7 points had a high negative
predictive value (99.7%) and a very low negative
likelihood ratio for high-risk CAD (<0.1) (Table 4).
Conversely, patients who scored $18 points had a
high speciﬁcity of 99.3% for high-risk CAD with a high
positive likelihood ratio of 8.48 (Table 4). The
Hosmer-Lemeshow statistic suggests that ﬁt of model
was adequate for the derivation cohort (p > 0.05).
Using the derivation cohort, the proposed model
for predicting presence of high-risk CAD had an area
under ROC curve of 0.76 (95% CI: 0.75 to 0.78) and
was signiﬁcantly better than the updated Diamond-
Forrester model (0.64 [95% CI: 0.62 to 0.67];
p < 0.001) (Figure 1). The model was applied in a
subgroup of 14,142 symptomatic patients, and the
area under the ROC curve was similar with 0.78 (95%
CI: 0.76 to 0.79). Calibration of the score was
acceptable at low and intermediate score values, but
it decreased at higher score values because of the
small number of cases (Figure 2).
VALIDATION COHORT. In an external validation set
of nonoverlapping patients comprising the CONFIRM
validation cohort and the University of Ottawa Heart
Institute Cardiac CT Registry, the model was robust
with an area under the curve of 0.71 (95% CI: 0.69 to
0.74) (Figure 3). The accuracy of the score and the
TABLE 4 Operating Characteristics for Each Threshold of High-Risk CAD Score in Derivation Cohort
Score
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
PLR
(95% CI)
NLR
(95% CI)
1 1.000 0.000 0.036 (0.034–0.039) — 1.000 —
0 1.000 0.000 0.036 (0.034–0.039) — 1.000 —
1 0.999 (0.997–1.000) 0.003 (0.002–0.004) 0.036 (0.034–0.039) 0.985 (0.957–1.000) 1.002 (0.999–1.004) 0.398 (0.055–2.862)
2 0.999 (0.997–1.000) 0.009 (0.008–0.010) 0.036 (0.034–0.039) 0.995 (0.986–1.000) 1.008 (1.005–1.010) 0.131 (0.018–0.936)
3 0.999 (0.997–1.000) 0.018 (0.017–0.020) 0.036 (0.034–0.039) 0.998 (0.993–1.000) 1.018 (1.015–1.021) 0.062 (0.009–0.439)
4 0.999 (0.997–1.000) 0.042 (0.039–0.044) 0.038 (0.035–0.040) 0.999 (0.997–1.000) 1.042 (1.039–1.046) 0.027 (0.004–0.194)
5 0.999 (0.997–1.000) 0.070 (0.067–0.073) 0.039 (0.036–0.041) 0.999 (0.998–1.000) 1.074 (1.070–1.079) 0.016 (0.002–0.116)
6 0.992 (0.986–0.998) 0.122 (0.118–0.126) 0.041 (0.038–0.043) 0.998 (0.996–0.999) 1.130 (1.121–1.138) 0.066 (0.031–0.137)
7 0.984 (0.976–0.992) 0.193 (0.188–0.198) 0.044 (0.041–0.047) 0.997 (0.995–0.999) 1.219 (1.206–1.232) 0.083 (0.049–0.139)
8 0.964 (0.951–0.976) 0.283 (0.277–0.289) 0.048 (0.045–0.051) 0.995 (0.994–0.997) 1.344 (1.324–1.365) 0.129 (0.092–0.181)
9 0.927 (0.910–0.944) 0.391 (0.385–0.397) 0.054 (0.050–0.058) 0.993 (0.991–0.995) 1.522 (1.490–1.555) 0.187 (0.147–0.236)
10 0.877 (0.855–0.899) 0.505 (0.498–0.511) 0.062 (0.058–0.067) 0.991 (0.989–0.993) 1.771 (1.722–1.821) 0.244 (0.204–0.291)
11 0.774 (0.747–0.802) 0.623 (0.617–0.629) 0.072 (0.066–0.077) 0.987 (0.985–0.988) 2.054 (1.975–2.137) 0.362 (0.320–0.410)
12 0.650 (0.618–0.682) 0.728 (0.723–0.734) 0.082 (0.076–0.089) 0.982 (0.980–0.984) 2.391 (2.268–2.521) 0.481 (0.439–0.526)
13 0.513 (0.480–0.546) 0.818 (0.813–0.823) 0.095 (0.087–0.104) 0.978 (0.976–0.980) 2.812 (2.622–3.016) 0.596 (0.556–0.638)
14 0.396 (0.363–0.428) 0.889 (0.885–0.893) 0.118 (0.106–0.129) 0.975 (0.973–0.977) 3.554 (3.250–3.887) 0.680 (0.645–0.718)
15 0.257 (0.228–0.286) 0.937 (0.934–0.940) 0.132 (0.116–0.149) 0.971 (0.969–0.973) 4.068 (3.597–4.601) 0.794 (0.76–0.825)
16 0.166 (0.142–0.191) 0.967 (0.965–0.969) 0.160 (0.136–0.184) 0.969 (0.966–0.971) 5.067 (4.302–5.967) 0.862 (0.837–0.888)
17 0.105 (0.085–0.125) 0.985 (0.984–0.987) 0.209 (0.171–0.247) 0.967 (0.965–0.969) 7.026 (5.641–8.751) 0.909 (0.888–0.930)
18 0.056 (0.041–0.071) 0.993 (0.992–0.994) 0.241 (0.183–0.300) 0.966 (0.963–0.968) 8.480 (6.193–11.612) 0.950 (0.935–0.966)
19 0.027 (0.017–0.038) 0.998 (0.997–0.998) 0.316 (0.211–0.420) 0.965 (0.962–0.967) 12.301 (7.620–19.859) 0.975 (0.964–0.986)
20 0.010 (0.004–0.017) 0.999 (0.999–1.000) 0.300 (0.136–0.464) 0.964 (0.962–0.967) 11.422 (5.247–24.867) 0.991 (0.984–0.997)
21 0.007 (0.001–0.012) 1.000 0.462 (0.191–0.733) 0.964 (0.962–0.966) 22.845 (7.694–67.834) 0.994 (0.988–0.999)
22 0.000 1.000 0.000 0.964 (0.962–0.966) — 1.000
NLR ¼ negative likelihood ratio; NPV ¼ negative predictive value; PLR ¼ positive likelihood ratio; PPV ¼ positive predictive value; other abbreviations as in Table 1.
TABLE 5 Proportion of Patients Classiﬁed by High-Risk CAD Score in Each Clinical
Probability Category and Predictive Accuracy of the Score
Clinical Probability
Derivation Cohort Validation Cohort
Patients
Patients With
Conﬁrmed HRA Patients
Patients With
Conﬁrmed HRA
Low (#7) 6,651 (27.4) 32 (0.5) 1,738 (23.7) 17 (1.0)
Intermediate (8–17) 17,397 (71.7) 796 (4.6) 5,547 (75.6) 324 (5.8)
High ($18) 203 (0.8) 49 (24.1) 48 (0.7) 8 (16.7)
All 24,251 877 (3.6) 7,333 349 (4.8)
Values are n (%).
CAD ¼ coronary artery disease; HRA ¼ high-risk anatomy.
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431proportion of patients classiﬁed into each probability
category were similar to those of the derivation group
(Table 5). The calibration of the score was also similar
in both derivation and validation groups (Figure 2).
DISCUSSION
This study derived a scoring system to predict high-
risk CAD in patients with suspected CAD, and it
includes variables that can be easily obtained from a
patient’s history. These variables are similar to
other clinical models used to predict obstructive
CAD (e.g., Morise, Duke, and Diamond-Forrester
scores), but our current variables were developed
in a diverse population from multiple centers,
thereby validating the model’s applicability (6–8).
This model appears to be most useful in identifying
those patients with the greatest likelihood of having
“high-risk coronary anatomy,” thereby identifying a
group that could beneﬁt most from ICA with or
without fractional ﬂow reserve measurements. All
other symptomatic patients could potentially be
diagnosed and stratiﬁed using available noninvasive
modalities such as coronary CTA, perfusion imaging,
or stress echocardiography.PROBABILITY OF HIGH-RISK CORONARY ARTERY
DISEASE. High-risk CAD is associated with more
frequent adverse events, and these patients typically
derive the greatest beneﬁt from revascularization
(18–23). Clinical trials have shown that, compared
with medical therapy, coronary artery bypass graft
signiﬁcantly improves survival of patients with high-
risk CAD (1,2,24). Therefore, patients with a high
probability of high-risk CAD should be considered for
deﬁnitive anatomic imaging (e.g., invasive angiog-
raphy) and possible revascularization. Conversely,
FIGURE 1 ROC Curves Comparing Model’s Ability to Predict High-Risk CAD With
Updated Diamond-Forrester Model in Derivation Cohort
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Our model had an area under the receiver operating characteristic (ROC) curve of 0.76,
which was signiﬁcantly better than the modiﬁed Diamond-Forrester model in predicting
high-risk coronary artery disease (CAD). HRA ¼ high-risk anatomy.
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Observed and expected probabilities of high-risk coronary artery disease (CA
scores, likely fromthesmall numberofcases.Ourmodelwasabletopredicth
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432patients with a low probability of high-risk CAD may
be initially treated with optimal medical therapy (4).
The COURAGE (Clinical Outcomes Utilizing Revascu-
larization and Aggressive Drug Evaluation) trial
compared outcomes of non–high-risk CAD patients
treated with medical therapy or with percutaneous
coronary intervention coupled with medical therapy
and concluded that revascularization did not signiﬁ-
cantly reduce mortality or other adverse cardiovas-
cular events in these patients (4). Patients with an
intermediate probability of high-risk CAD should be
further investigated and stratiﬁed noninvasively.
Our model contains 9 variables derived from 877
events, is sufﬁciently robust, and was validated in an
independent cohort with similar results (25). The
performance of our scoring system is compared with
the updated Diamond-Forrester model in predicting
CAD, and our model performs signiﬁcantly better,
with nonoverlapping CI.
This study population consists of patients with
stable CAD who were referred for coronary CTA, a
highly speciﬁc and sensitive method for detecting
coronary artery stenosis (15). In fact, a meta-analysis
suggests that coronary CTA should be used to rulecore in Derivation and Validation Cohorts
 CAD Score
10 11 12 13 14 15 16 17 18 19 20
 CAD Score
10 11 12 13 14 15 16 17 18 19 20
Observed
D) were similar for low and intermediate scores and decreased at higher
igh-riskCADwithsimilaraccuracy inbothderivationandvalidationgroups.
FIGURE 3 ROC Curves of High-Risk CAD Score in
Validation Cohort
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The area under receiver operating characteristic (ROC) curve in
the external validation group was robust at 0.71 (95% conﬁ-
dence interval: 0.69 to 0.74), conﬁrming applicability of the
model. CAD ¼ coronary artery disease.
PERSPECTIVES
CLINICAL COMPETENCIES: A scoring system using clinical
variables may be used to identify patients at high and low
pre-test probability of having high-risk CAD. This scoring
system may detect those who beneﬁt from a trial of medical
therapy and those who may beneﬁt most from an invasive
strategy.
TRANSLATIONAL OUTLOOK: Additional studies are needed
to validate this scoring system further in the stable outpatient
population referred for noninvasive testing.
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433out obstructive CAD in patients with intermediate
probability, to avoid inappropriate ICA testing (26).
Given the size and diverse patient population
in the study, these results should be applicable to
stable symptomatic outpatients with suspected CAD.
A high score ($18) is speciﬁc (99.3%) for high-risk
CAD and could sway a physician to proceed directly
to ICA.
STUDY LIMITATIONS. Although, the current gold
standard for diagnosing obstructive CAD is ICA, this
study uses coronary CTA to deﬁne high-risk CAD.
Thus, these results will be subject to the diagnostic
inaccuracies of coronary CTA. An earlier study
compared the performance of noninvasive coronary
CTA with ICA in detecting high-risk CAD and reported
that coronary CTA was both highly sensitive and
highly speciﬁc (sensitivity, 100%; speciﬁcity, 95%),
and it had a very high positive likelihood ratio
(18.0) and a reasonable positive predictive value of
76.9% (15).
Referral bias may be a factor; differences in clin-
ical practice across the 12 sites can inﬂuence the
selection of patients referred for coronary CTA. The
CONFIRM registry sets standardized deﬁnitions forcardiovascular risk factors across centers, and it en-
lists only centers where coronary CTA is incorpo-
rated into daily practice, with uniform collection of
major categories including demographics, earlier
CAD, and revascularization history (9). This stan-
dardization helps to reduce inconsistencies among
protocols and guidelines across sites.
We also recognize that patients with severe
symptoms and other high-risk factors are more likely
to be referred directly to ICA. Therefore, our study
population may be more reﬂective of patients with
stable CAD in which ICA may not be immediately
indicated.
Blood results and medications were not included
into the risk model. The intention was to create a
simple and easily applied model that was built
entirely on clinical factors that could be used at every
clinical encounter. In addition, medications were
excluded from analysis. Because the duration of
medication therapy was not captured, some medica-
tions may have been recently initiated in response to
the suspicion of CAD and may introduce bias into the
model.
CONCLUSIONS
We propose a scoring system based on clinical vari-
ables that can be used to identify patients at high and
low risk of having high-risk CAD. Identiﬁcation of
these populations may detect those who may beneﬁt
from a trial of medical therapy and those who may
beneﬁt most from an invasive strategy. This score
likely applies to those patients with a stable low to
intermediate risk for CAD.
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